Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

被引：0

作者：

Geissler, Klaus ^{[1
,2
]}

Koristek, Zdenek ^{[3
]}

Del Castillo, Teresa Bernal ^{[4
]}

Novak, Jan ^{[5
,6
]}

Macias, Gabriela Rodriguez ^{[7
]}

Metzelder, Stephan ^{[8
]}

Illes, Arpad ^{[9
]}

Nagy, Agnes ^{[10
]}

Mayer, Jiri ^{[11
,12
]}

Arnan Sangerman, Montserrat ^{[13
]}

Keating, Mary-Margaret ^{[14
]}

Krauter, Juergen ^{[15
]}

Lunghi, Monia ^{[16
]}

Fracchiolla, Nicola ^{[17
]}

Platzbecker, Uwe ^{[18
]}

Santini, Valeria ^{[19
]}

Chan, Danna ^{[20
]}

Mirakhur, Beloo ^{[20
]}

Sano, Yuri ^{[20
]}

Oganesian, Aram ^{[20
]}

Keer, Harold N. ^{[20
]}

Luebbert, Michael ^{[21
]}

机构：

[1] Clin Hietzing, Vienna, Austria

[2] Sigmund Freud Univ, Vienna, Austria

[3] Univ Hosp Ostrava, Ostrava, Czech Republic

[4] Hosp Univ Cent Asturias, ISPA, IUOPA, Oviedo, Spain

[5] Charles Univ Prague, Prague, Czech Republic

[6] Fac Hosp Kralovske Vinohrady, Prague, Czech Republic

[7] Hosp Univ Gregorio Maranon, Madrid, Spain

[8] Philipps Univ Marburg, Marburg, Germany

[9] Univ Debrecen, Dept Hematol, Fac Med, Debrecen, Hungary

[10] Univ Pecs, Pecs, Hungary

[11] Masaryk Univ, Brno, Czech Republic

[12] Univ Hosp Brno, Brno, Czech Republic

[13] Univ Barcelona, Dept Hematol, Inst Catala Oncol, Hosp Duran & Reynals,Inst Invest Biomed Bellvitge, Barcelona, Spain

[14] Queen Elizabeth II QEII Hlth Sci Ctr, Halifax, NS, Canada

[15] Stadt Klinikum Braunschweig, Dept Hematol & Oncol, Braunschweig, Germany

[16] Univ Piemonte Orientale, Dept Translat Med, Div Hematol, Novara, Italy

[17] Fdn IRCCS Ca Granda Osped Maggiore Policlin Milan, Hematol Unit, Milan, Italy

[18] Univ Hosp Leipzig, Dept Hematol, Leipzig, Germany

[19] Univ Florence, DMSC, AOU Careggi, MDS Unit, Florence, Italy

[20] Astex Pharmaceut Inc, Pleasanton, CA USA

[21] Univ Med Ctr Freiburg, Freiburg, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173092

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
Atluri, Himachandana
Maiti, Abhishek
Sasaki, Koji
Daver, Naval
Alvarado, Yesid
Hossain, Md Feroz
Wang, Xuemei
Pemmaraju, Naveen
Takahashi, Koichi
Borthakur, Gautam
Ferrajoli, Alessandra
Short, Nicholas
Abbas, Hussein A.
Ravandi, Farhad
Jabbour, Elias
Andreeff, Michael
Garcia-Manero, Guillermo
Kantarjian, Hagop
Konopleva, Marina
DiNardo, Courtney D.
BLOOD, 2022, 140 : 6170 - 6172
[32] A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Mawad, Raya
Becker, Pamela S.
Hendrie, Paul C.
Scott, Bart L.
Wood, Brent L.
Dean, Carol
Sandhu, Vicky
Deeg, H. Joachim
Walter, Roland B.
Wang, Lixia
Singer, Jack
Estey, Elihu H.
Pagel, John
BLOOD, 2014, 124 (21)
[33] Results of a phase 1 b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients? 65 years ineligible for standard induction therapy.
Pollyea, Daniel Aaron
Dinardo, Courtney Denton
Thirman, Michael J.
Letai, Anthony
Wei, Andrew H.
Jonas, Brian Andrew
Arellano, Martha Lucia
Frattini, Mark G.
Kantarjian, Hagop M.
Chyla, Brenda
Zhu, Ming
Potluri, Jalaja
Humerickhouse, Rod
Mabry, Mack H.
Konopleva, Marina
Pratz, Keith William
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[34] RESULTS OF A PHASE 1B STUDY OF VENETOCLAX PLUS DECITABINE OR AZACITIDINE IN UNTREATED ACUTE MYELOID LEUKEMIA PATIENTS ≥65 YEARS INELIGIBLE FOR STANDARD INDUCTION THERAPY
Pollyea, D. A.
Di Nardo, C.
Thirman, M.
Letai, A.
Wei, A.
Jonas, B. A.
Arellano, M.
Frattini, M.
Kantarjian, H.
Chyla, B.
Zhu, M.
Potluri, J.
Humerickhouse, R.
Mabry, M.
Konopleva, M.
Pratz, K.
HAEMATOLOGICA, 2016, 101 : 44 - 44
[35] Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)
Rummelt, Christoph
Grishina, Olga
Schmoor, Claudia
Crysandt, Martina
Heuser, Michael
Goetze, Katharina S.
Schlenk, Richard F.
Doehner, Konstanze
Salih, Helmut R.
Heil, Gerhard
Mueller-Tidow, Carsten
Brugger, Wolfram
Kuendgen, Andrea
de Wit, Maike
Giagounidis, Aristoteles
Scholl, Sebastian
Neubauer, Andreas
Krauter, Juergen
Bug, Gesine
Al-Ali, Haifa Kathrin
Waesch, Ralph
Becker, Heiko
May, Annette M.
Duyster, Justus
Hackanson, Bjoern
Ganser, Arnold
Doehner, Hartmut
Luebbert, Michael
HAEMATOLOGICA, 2023, 108 (08) : 2244 - 2248
[36] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study
Halpern, Anna B.
Buckley, Sarah A.
Othus, Megan
Huebner, Emily M.
Orlowski, Kaysey F.
Scott, Bart L.
Perdue, Andrea M.
Smith, Heather A.
Becker, Pamela S.
Hendrie, Paul C.
Cassone, Stephanie
Chen, Tara L.
Stirewalt, Derek L.
Estey, Elihu H.
Walter, Roland B.
BLOOD, 2016, 128 (22)
[37] Updated results of a phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene reexpression, demethylation, and clinical response.
Klisovic, R. B.
Blum, W.
Hackanson, B.
Kefauver, C.
Liu, S.
Liu, Z.
Chan, K. K.
Plass, C.
Grever, M. R.
Byrd, J. C.
Marcucci, G.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 340S - 340S
[38] Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial
U Jehn
S Suciu
X Thomas
F Lefrère
P Muus
Z Berneman
J-P Marie
F Adamo
G Fillet
F Nobile
F Ricciuti
G Leone
V Rizzoli
M Montanaro
F Beeldens
P Fazi
F Mandelli
R Willemze
T de Witte
S Amadori
Leukemia, 2006, 20 : 1723 - 1730
[39] Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial
Jehn, U.
Suciu, S.
Thomas, X.
Lefrere, F.
Muus, P.
Berneman, Z.
Marie, J-P
Adamo, F.
Fillet, G.
Nobile, F.
Ricciuti, F.
Leone, G.
Rizzoli, V.
Montanaro, M.
Beeldens, F.
Fazi, P.
Mandelli, F.
Willemze, R.
de Witte, T.
Amadori, S.
LEUKEMIA, 2006, 20 (10) : 1723 - 1730
[40] Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)
Kantarjian, Hagop M.
Begna, Kebede H.
Altman, Jessica K.
Goldberg, Stuart L.
Sekeres, Mikkael A.
Strickland, Stephen A.
Arellano, Martha L.
Claxton, David F.
Baer, Maria R.
Gautier, Marc
Berman, Ellin
Seiter, Karen
Solomon, Scott R.
Schiller, Gary J.
Luger, Selina M.
Butrym, Aleksandra
Gaidano, Gianluca
Thomas, Xavier G.
Montesinos, Pau
Rizzieri, David A.
Quick, Donald P.
Venugopal, Parameswaran
Gaur, Rakesh
Maness, Lori J.
Kadia, Tapan M.
Ravandi, Farhad
Buyse, Marc E.
Chiao, Judy H.
CANCER, 2021, 127 (23) : 4421 - 4431

← 1 2 3 4 5 →